Press Release

For Immediate Distribution

SUNWAY HEALTHCARE

SUNWAY HEALTHCARE DELIVERS SOLID SECOND QUARTER GROWTH WITH REVENUE UP 30% AND PROFIT AFTER TAX NEARLY DOUBLING

Revenue rises 30% year-on-year supported by higher patient volumes, improved bed occupancy and stronger hospital activities; reported EBITDA climbs 43% and profit after tax jumps 89%

---

20 August 2026, KUALA LUMPUR – Sunway Healthcare Holdings Berhad ("**SHH**" or the **"Group")**, one of Malaysia's leading integrated private healthcare providers, today announced its financial results for the second quarter and six-month ended 30 June 2026 ("**Q2FY2026**" and "**H1FY2026**", respectively).

The Group delivered record quarterly revenue and stronger earnings in Q2FY2026, reflecting progressive capacity activation, higher patient volumes and improving operating leverage across its hospital network.

Key Financial and Operating Highlights (Q2FY2026)

- Total licensed beds expanded by 13% year-on-year ("**y-o-y**") to 1,855 beds. As at 30 June 2026, the Group had total bed capacity of 2,072 beds, providing further headroom for near-term growth.
- Revenue rose 30% y-o-y to a record RM672.9 million (Q2FY2025: RM518.6 million), driven primarily by stronger patient volumes across the Group's hospital network and robust revenue contributions from Sunway Medical Centre ("**SMC**") Sunway City, SMC Damansara and SMC Ipoh.
- Bed occupancy rate rose to 73% (Q2FY2025: 67%), as inpatient admissions increased by 19% y-o-y to 32,599, supported by 208 additional licensed beds y-o-y and improved utilisation at SMC Damansara and SMC Ipoh. Revenue per inpatient admission grew 8% y-o-y to RM12,515 (Q2FY2025: RM11,587).
- Reported EBITDA increased 43% y-o-y to RM158.8 million (Q2FY2025: RM111.2 million), with earnings growth outpacing revenue growth as higher patient volumes and improved utilisation supported stronger operating leverage across the hospital network. EBITDA margin correspondingly strengthened by 2.2 percentage points to 23.6% (Q2FY2025: 21.4%).
- Excluding non-recurring costs, normalised EBITDA(1) rose 44% y-o-y to RM161.3 million (Q2FY2025: RM112.2 million), with adjusted EBITDA margin expanding by 2.4 ppts to 24.0% (Q2FY2025: 21.6%), reflecting the improvement in the Group's underlying operating performance.
- Profit attributable to owners of the Company increased 89% y-o-y to RM78.2 million (Q2FY2025: RM41.4 million), underpinned by stronger operating performance, notwithstanding higher depreciation from the expanded asset base.
- Net gearing ratio improved significantly from 42% (31 December 2025) to 10% (30 June 2026) following the Group's IPO.

Note: (1) Normalised EBITDA is a non-MFRS financial measure and is presented to provide additional insight into the Group's underlying operating performance. It is not a substitute for EBITDA or profit measures prepared under MFRS.

- The strong Q2FY2026 performance lifted H1FY2026 revenue to RM1.26 billion, up 27% y-o-y, and reported EBITDA to RM270.8 million, up 32% y-o-y. Profit attributable to owners of the Company increased by 39% to RM111.5 million, providing a solid base for the Group entering the second half of the year.

Q2FY2026 Performance Overview

Revenue growth accelerated across all hospitals following the seasonally softer first quarter. The Group's flagship SMC Sunway City remained the principal revenue and earnings contributor, while its mature hospitals, SMC Velocity and SMC Penang, continued to benefit from stronger patient activities and revenue intensity. SMC Damansara and SMC Ipoh, which are the newly operational hospitals, continued to scale as their combined revenue contribution reached 11% (Q2FY2025: 5%) as both hospitals progressed further into positive EBITDA contribution.

Notwithstanding ongoing geopolitical uncertainties, foreign patient revenue remained a key growth pillar for the Group, increasing 31% y-o-y, driven primarily by patient inflows from Indonesia, China and Cambodia. Local patient revenue also expanded 30% y-o-y, reflecting continued demand across the Group's local and foreign patient segments.

EBITDA growth outpaced topline performance, as higher patient volumes, capacity activation and bed occupancy translated into stronger operating leverage across the network. While the flagship and mature hospitals drove much of the earnings uplift, improving contributions from SMC Damansara and SMC Ipoh progressively reduced the gestation drag from these newer hospitals. Meanwhile, operating expenses also grew at a slower pace than revenue.

Profit before tax rose 66% y-o-y to RM93.2 million, underpinned by stronger operating performance, partially offset by higher depreciation and amortisation arising from the expanded asset base.

Operational Developments

The Group strengthened its leadership bench with effect from 1 July 2026, with Dr Seow Vei Ken elevated to Group Chief Medical Director. In his new role, Dr Seow will provide group-wide clinical leadership, strengthen medical governance and advance clinical excellence across the hospital network. Meanwhile, Erica Lam was appointed Chief Executive Officer of SMC Sunway City to lead the flagship hospital in its next phase of growth. These appointments reinforce the Group's strategy of complementing its expanding hospital network and advanced infrastructure with the clinical leadership, specialist depth and operational talent needed to sustain long-term growth.

The Group's continued focus on clinical excellence and sustainable healthcare was also recognised during the quarter. SMC Sunway City was ranked No.1 in Malaysia and Asia Pacific for Neurology and recognised across seven other specialties in Newsweek's Best Specialized Hospitals Asia Pacific 2026. Separately, SMC Velocity and SMC Sunway City were named among Newsweek's World's Greenest

Hospitals 2026, with SMC Velocity being one of only 12 hospitals in Asia Pacific to receive the highest five-leaf performance designation and SMC Sunway City receiving four leaves.

Demand for the Group's specialised and complementary healthcare services also continued to gain traction. Sunway Fertility Centre Kota Bharu commenced operations in July 2026, marking the Group's entry into the East Coast of Peninsular Malaysia. In senior living, Sunway Sanctuary achieved positive EBITDA in H1FY2026, with demand continuing to build ahead of its Phase 2 capacity expansion planned for 2027.

Greenfield execution is progressing, including the preparatory works for SMC Iskandar Puteri and SMC Seremban Sentral. Together with SMC Putrajaya, these projects form part of the Group's plan to expand its hospital network and increase total bed capacity to more than 3,400 beds by 2032, subject to the relevant approvals and prevailing project timelines.

Outlook

Q2FY2026 strengthened the Group's H1FY2026 performance, supported by broad-based growth across the hospital network, improved operating leverage and rising contributions from the newer hospitals. With patient demand remaining healthy, expanded capacity being progressively absorbed, coupled with SMC Damansara and SMC Ipoh advancing along their ramp-up curves, the Group enters the second half of 2026 with stronger earnings momentum and a more balanced contribution across its portfolio.

As at 30 June 2026, the Group had 1,855 licensed beds and 217 new beds available for licensing, bringing total capacity to 2,072 beds. Subsequent to the quarter-end, the completion of SMC Sunway City, Tower F increased the total capacity to 2,271 beds. The Group continues to make progress on its next phase of brownfield expansion at SMC Penang and SMC Damansara, with preparatory activities advancing in support of their respective development programmes. Together with the progressive licensing and operationalisation of completed capacity, these initiatives are expected to increase total bed capacity to approximately 2,400 beds by 2028. The Group will continue to advance its brownfield and greenfield expansion plans, supported by its strong financial position following the listing.

The MediAsas pilot, scheduled to run from end-July to October 2026 in the Klang Valley, is expected to provide a more affordable base medical insurance option and support an orderly transition towards a more sustainable medical insurance ecosystem. The Group will continue preparing for the planned MediAsas rollout and the phased implementation of the Diagnosis-Related Group payment framework, while engaging insurers and takaful operators on sustainable reimbursement arrangements.

While geopolitical developments may continue to create volatility in regional travel, freight and input costs, the underlying demand for private healthcare and medical tourism remains constructive. The Group will continue to broaden its foreign patient source markets, referral channels and payor partnerships, while maintaining diversified sourcing, adequate inventory buffers and disciplined cost management.

Press Release

For Immediate Distribution

Supported by favourable long-term healthcare demographics, Malaysia's established position as a regional medical tourism destination and the Group's expanding capacity and clinical capabilities, the Group remains positive about its prospects for FY2026. SHH will continue to focus on converting patient-volume growth and capacity activation into sustainable earnings while preserving accessibility, clinical excellence, operational resilience and financial discipline.

***

For media enquiries, please contact:

Puteri Farhana (Farah): puteriffmi@sunway.com.my, +6012-777 6049

Sarah Chew: sarahcsm@sunway.com.my, +6016-225 9991

For investor relations, please contact:

Victor Geh: victorgck@sunway.com.my, +6016-421 1008

About Sunway Healthcare Holdings Berhad

Sunway Healthcare Holdings (SHH), through its subsidiaries, is one of the leading integrated private healthcare providers with an extensive network of hospitals and healthcare services in Malaysia.

SHH's network includes its flagship quaternary hospital Sunway Medical Centre in Sunway City Kuala Lumpur, tertiary hospitals Sunway Medical Centre Velocity, Sunway Medical Centre Penang, Sunway Medical Centre Damansara, and Sunway Medical Centre Ipoh, ambulatory care centres at Sunway Specialist Centre Damansara and Sunway Fertility Centre (Kuching and Kota Bharu) and supportive and complementary care centres at Sunway TCM Centre and Sunway Home Healthcare. SHH also operates Sunway Sanctuary, an integrated senior living facility annexed to Sunway Medical Centre Sunway City Kuala Lumpur.

At the heart of SHH are skilled and experienced healthcare professionals, supported by some of the most advanced medical equipment available today, attracting international patients from over the world.

As part of its expansion strategy to provide more communities with access to quality healthcare, SHH will increase its footprint all over Malaysia with tertiary hospitals in Seremban (Negeri Sembilan), Putrajaya, and Iskandar Puteri (Johor). With this growth, SHH expects to have a combined capacity of over 3,400 beds among its network of hospitals by 2032.

To learn more, visit https://www.sunwayhealthcaregroup.com/

Issued by: Sunway Healthcare Holdings Berhad

Date: 20 August 2026